a frought cohort too... read about IIL - all of their reseach was fantastic, many happy early trial patients in remission, and came down to the wire of FDA approval - took a US senator down with it -early in Trumps admin ... when the double blind studies came back negative. reborn as ATX w great promise in antiflammatory treatments but less MS emphasis.
a frought cohort too... read about IIL - all of their reseach...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.23%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.04 | $14.57M | 13.49M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21024 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 241 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |